W. Marston Linehan

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-01-23

• MA02.03 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Long-Term Follow-Up From the Phase 1/2 TRIDENT-1 Trial

  Journal of Thoracic Oncology · 2025-10-01 · 1 citations

• Adverse events associated with sequential immune checkpoint inhibitor and alectinib in patients with ALK-rearranged advanced non-small-cell lung cancer

  ESMO Open · 2025-10-01 · 2 citations

• EP.06.53 c-MET Expression in Non-Squamous NSCLC: Molecular Correlation and Interobserver and Intersample Concordance on Scoring

  Journal of Thoracic Oncology · 2025-10-01

• PL02.15 Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC

  Journal of Thoracic Oncology · 2025-10-01 · 3 citations

• Defining the Histopathological, Clinical, and Genetic Characteristics of Familial BAP1-associated Renal Cell Carcinoma

  European Urology · 2025-09-08 · 2 citations

• 2013P Repotrectinib in adult and pediatric patients with NTRK+ advanced solid tumors: Updated results from the TRIDENT-1 and CARE trials

  Annals of Oncology · 2025-09-01

• Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

  Nature Communications · 2025-08-19 · 9 citations

• Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors

  Investigational New Drugs · 2025-08-01 · 2 citations

• A shape theorem for BBM in a periodic environmentPreprint

  ArXiv.org · 2025-07-14

• A plain language summary of two trials for larotrectinib in people with TRK fusion-positive lung cancer to learn how well the drug works and how safe it is

  Future Oncology · 2025-06-20

• TEAD1 condensates are transcriptionally inactive storage sites on the pericentromeric heterochromatin in cancer cellsPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-05-03 · 1 citations

• Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study

  The Lancet Oncology · 2025-04-12 · 26 citations

• Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies

  Clinical Lung Cancer · 2025-03-27 · 3 citations

• 72P Efficacy and safety of larotrectinib as first-line treatment for adult patients with TRK fusion cancer

  ESMO Open · 2025-03-01

• Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]

  Lung Cancer · 2025-02-23

• Exploring the efficacy of belzutifan in the treatment of renal cell carcinoma associated with von Hippel-Lindau disease: A comparative analysis with external control arm.

  Journal of Clinical Oncology · 2025-02-10

• GUK1 activation is a metabolic liability in lung cancer

  Cell · 2025-02-06 · 14 citations

• Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors

  Annals of Oncology · 2025-02-04 · 48 citations

• Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer

  Trends in cancer · 2025-01-30 · 7 citations